A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Beckman Symposium

The 23rd Beckman Symposium - Antibody Engineering
Friday, December 6, 2013
8:30 a.m. to 5 p.m.

City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

The 23rd Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
2013 Speaker List:
Patrick A. Baeuerle, Ph.D.
Amgen Research, Munich, Germany
Shmuel Cabilly, Ph.D.
High Tech Investor and Board Member
Paul Carter, Ph.D.
Herbert A. Heynecker, Ph.D.
Advisor, Thuja Capital
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
Arthur D. Riggs, Ph.D.
City of Hope
Peter Senter, Ph.D.
Seattle Genetics, Inc.
E. Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
Anna Wu, Ph.D.
University of California, Los Angeles


In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.


Symposium Program

8:30 to 9 a.m.

9 to 9:10 a.m.
David Horne, Ph.D.
Interim Director, Beckman Research Institute
City of Hope
9:10 to 9:20 a.m.
Overview of Morning Session
John E. Shively, Ph.D.
City of Hope
9:20 to 10:10 a.m.
Early Recombinant Antibody Studies at City of Hope and Genentech
Arthur D. Riggs, Ph.D., City of Hope
Shmuel Cabilly, Ph.D., High Tech Investor and
Board Member Herbert Heynecker, Ph.D., Advisor, Thuja Capital
10:10 to 10:30 a.m.
10:30 to 11:20 a.m.
Engineered Antibodies for Molecular Imaging in Oncology and Beyond
Anna Wu, Ph.D., University of California
Los Angeles
11:20 a.m. to 12:10 p.m.
From Knobs-into-Holes to Onartuzumab
Paul Carter, Ph.D., Genentech
12:10 to 1:10 p.m.
1:10 to 1:20 p.m.
Overview of Afternoon Session
Andrew Raubitschek, M.D.
City of Hope
1:20 to 2:10 p.m.
Combinatorial and Evolutionary Engineering:
The Binders and Targets
Andreas Plückthun, Ph.D.
University of Zurich, Switzerland
2:10 to 3 p.m.
Targeting FcRn for Therapy
Sally Ward, Ph.D.
University of Texas Southwestern Medical Center, Dallas
3 to 3:20 p.m.
3:20 to 4:10 p.m.
Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics, Inc.
4:10 to 5 p.m.
Cancer Therapy by T Cell-engaging
Bispecific Antibodies
Patrick Baeuerle, Ph.D., Amgen Research,
Munich, Germany


*Registration and lunches are limited to the first 350 registrants*
Research Overview
Research pioneered at City of Hope has improved the lives of men, women and children throughout the world.
Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.

  • Learn more about becoming a patient or getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the ...
  • Counter-intuitive though it might seem, a prostate cancer diagnosis shouldn’t always lead to immediate prostate cancer treatment. Although prostate cancer is the second-leading cancer killer of men, behind lung cancer, and causes more than 29,000 deaths in the U.S. each year, in many cases, the tumors are...
  • Radiology is one of the cornerstones of any hospital. It is a key diagnostic branch of medicine essential for the initial diagnosis of many diseases and has an important role in monitoring a patient’s treatment and predicting outcome. Radiology is the specialty considered to be both the “eyes” and “ears” of med...
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...